158 related articles for article (PubMed ID: 38771485)
1. Resmetirom: First Approval.
Keam SJ
Drugs; 2024 Jun; 84(6):729-735. PubMed ID: 38771485
[TBL] [Abstract][Full Text] [Related]
2. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Harrison SA; Bedossa P; Guy CD; Schattenberg JM; Loomba R; Taub R; Labriola D; Moussa SE; Neff GW; Rinella ME; Anstee QM; Abdelmalek MF; Younossi Z; Baum SJ; Francque S; Charlton MR; Newsome PN; Lanthier N; Schiefke I; Mangia A; Pericàs JM; Patil R; Sanyal AJ; Noureddin M; Bansal MB; Alkhouri N; Castera L; Rudraraju M; Ratziu V;
N Engl J Med; 2024 Feb; 390(6):497-509. PubMed ID: 38324483
[TBL] [Abstract][Full Text] [Related]
3. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
[TBL] [Abstract][Full Text] [Related]
4. The first MASH drug therapy on the horizon: Current perspectives of resmetirom.
Petta S; Targher G; Romeo S; Pajvani UB; Zheng MH; Aghemo A; Valenti LVC
Liver Int; 2024 Jul; 44(7):1526-1536. PubMed ID: 38578141
[TBL] [Abstract][Full Text] [Related]
5. Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH.
Harrison SA; Bashir M; Moussa SE; McCarty K; Pablo Frias J; Taub R; Alkhouri N
Hepatol Commun; 2021 Apr; 5(4):573-588. PubMed ID: 33860116
[TBL] [Abstract][Full Text] [Related]
6. Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196).
Alkhouri N
Expert Opin Investig Drugs; 2020 Feb; 29(2):99-101. PubMed ID: 31868036
[No Abstract] [Full Text] [Related]
7. A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply.
Harrison SA; Taub R
N Engl J Med; 2024 May; 390(17):1632-1633. PubMed ID: 38692302
[No Abstract] [Full Text] [Related]
8. Resmetirom: The First Food and Drug Administration-Approved Medication for Nonalcoholic Steatohepatitis (NASH).
Guirguis E; Dougherty J; Thornby K; Grace Y; Mack K
Ann Pharmacother; 2024 Jun; ():10600280241259528. PubMed ID: 38887011
[TBL] [Abstract][Full Text] [Related]
9. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis.
Kannt A; Wohlfart P; Madsen AN; Veidal SS; Feigh M; Schmoll D
Br J Pharmacol; 2021 Jun; 178(12):2412-2423. PubMed ID: 33655500
[TBL] [Abstract][Full Text] [Related]
10. Resmetirom for treatment of MASH.
Sookoian S; Pirola CJ
Cell; 2024 Jun; 187(12):2897-2897.e1. PubMed ID: 38848671
[TBL] [Abstract][Full Text] [Related]
11. Resmetirom (Rezdiffra) for metabolic dysfunction-associated steatohepatitis.
Med Lett Drugs Ther; 2024 Apr; 66(1701):65-66. PubMed ID: 38691644
[No Abstract] [Full Text] [Related]
12. Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis?
Vidal-Cevallos P; Chávez-Tapia N
Med; 2024 May; 5(5):375-376. PubMed ID: 38733968
[TBL] [Abstract][Full Text] [Related]
13. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis.
Harrison SA; Ratziu V; Anstee QM; Noureddin M; Sanyal AJ; Schattenberg JM; Bedossa P; Bashir MR; Schneider D; Taub R; Bansal M; Kowdley KV; Younossi ZM; Loomba R
Aliment Pharmacol Ther; 2024 Jan; 59(1):51-63. PubMed ID: 37786277
[TBL] [Abstract][Full Text] [Related]
14. Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH).
Luong XG; Stevens SK; Jekle A; Lin TI; Gupta K; Misner D; Chanda S; Mukherjee S; Williams C; Stoycheva A; Blatt LM; Beigelman LN; Symons JA; Raboisson P; McGowan D; Vandyck K; Deval J
PLoS One; 2020; 15(12):e0240338. PubMed ID: 33306682
[TBL] [Abstract][Full Text] [Related]
15. Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life.
Younossi ZM; Stepanova M; Taub RA; Barbone JM; Harrison SA
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1354-1361.e7. PubMed ID: 34329774
[TBL] [Abstract][Full Text] [Related]
16. Resmetirom's approval: Highlighting the need for comprehensive approaches in NASH therapeutics.
Alshehade SA
Clin Res Hepatol Gastroenterol; 2024 May; 48(7):102377. PubMed ID: 38772519
[TBL] [Abstract][Full Text] [Related]
17. Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis.
Karim G; Bansal MB
touchREV Endocrinol; 2023 May; 19(1):60-70. PubMed ID: 37313239
[TBL] [Abstract][Full Text] [Related]
18. Editorial: Resmetirom - a promising treatment option for NASH and liver fibrosis.
Targher G
Aliment Pharmacol Ther; 2024 Jan; 59(1):128-129. PubMed ID: 38085941
[No Abstract] [Full Text] [Related]
19. TG68, a Novel Thyroid Hormone Receptor-β Agonist for the Treatment of NAFLD.
Caddeo A; Kowalik MA; Serra M; Runfola M; Bacci A; Rapposelli S; Columbano A; Perra A
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884910
[TBL] [Abstract][Full Text] [Related]
20. Resmetirom proves positive for NASH with liver fibrosis.
Ray K
Nat Rev Gastroenterol Hepatol; 2024 Apr; 21(4):218. PubMed ID: 38360990
[No Abstract] [Full Text] [Related]
[Next] [New Search]
